Dabrafenib is a potent BRAF inhibitor and in addition we detected BRAF mutations as a sensitivity marker in thyroid carcinoma (Figure 4D, Figure 4—figure supplement 3D). Here, BRAF is linked to thyroid gland carcinoma.